Application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury

A traumatic brain injury and inhibitor technology, applied in the field of biomedicine, can solve problems such as the unclear mechanism of ferroptosis

Inactive Publication Date: 2020-05-12
SUZHOU UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, the mechanism of ferroptosis in traumatic brain injury is still unclear, and there is no report of Liproxstatin-1 in the treatment of traumatic brain injury, especially its effect on cerebral edema, blood-brain barrier permeability and anxiety cognition caused by traumatic brain injury. The effects of dysfunction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury
  • Application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury
  • Application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] (1) Drug preparation and administration method: referring to the previous research basis and preliminary experimental results, LIP-1 (TargetMol Company, product number: T2376) was formulated into three concentrations: 5mg / kg, 10mg / kg and 15mg / kg. The preparation method is as follows: according to the instructions, LIP-1 is dissolved in DMSO, and then prepared to the required concentration with medical physiological saline. LIP-1 was administered by intraperitoneal injection 1 h after TBI, once a day until the day before sacrifice.

[0039] (2) Animal grouping: There are the following five situations: ①After TBI protein time-course change experiment, 6-week-old ICR mice were randomly divided into eight groups, 5 in each group, respectively: Sham, 6h, 12h, 1d, 2d , 3d, 7d and 14d. ② Iron deposition Perl iron staining experiment, 6-week-old ICR mice were randomly divided into seven groups, 5 mice in each group, namely: Sham, 6h, 12h, 1d, 3d, 7d and 14d. ③ For the determi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury, and belongs to the technical field of biomedicines. The system of the ferroptosis inhibitor Liproxstatin-1 illustrates a time-course changing process (from 6h to 14d) of ferroptosis-related protein expression and occurrence of iron deposits after traumatic brain injury; meanwhile, the Liproxstatin-1 is dosed through an abdominal cavity after a person suffers from traumatic brain injury for 1 hour, which proves that the Liproxstatin-1 can alleviate cerebraledema and blood-brain barrier permeability caused by the traumatic brain injury; the findings proves that the Liproxstatin-1 has an improvement effect on exercise and learning memory impairment caused by the traumatic brain injury; the confirmation shows that the Liproxstatin-1 can obviously improve anxiety and cognitive functions caused by TB1; and in addition, revelation shows that a protectioneffect of the Liproxstatin-1 is related with up-regulation of FTH1 and Nrf2 and down-regulation of expression of NOX2 caused by reversion of TB1. An evidence is provided for using of the Liproxstatin-1 as a novel medicine for treating the traumatic brain injury.

Description

technical field [0001] The invention relates to the application of Liproxstatin-1, a ferroptosis inhibitor, in the preparation of medicines for treating traumatic brain injury, and belongs to the technical field of biomedicine. Background technique [0002] Traumatic brain injury (TBI) is an important cause of death and long-term disability in young patients, with prominent characteristics of high incidence, high mortality and high disability rate. Although with the continuous development of science and technology and diagnosis and treatment, many clinical methods (such as surgical treatment, intracranial pressure reduction and anticonvulsions, etc.) are used to intervene in TBI, but they still cannot prevent the occurrence and development of secondary brain injury. And the means are quite scarce, especially the lack of drug treatment, which seriously affects the prognosis of patients. Therefore, it is imperative to fully study the pathophysiological changes after traumatic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/498A61P25/00A61P25/28A61P25/22
CPCA61K31/498A61P25/00A61P25/28A61P25/22
Inventor 罗承良芮同宇李倩倩陶陆阳
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap